These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate. de Pilla Varotti F; Botelho AC; Andrade AA; de Paula RC; Fagundes EM; Valverde A; Mayer LM; Mendonça JS; de Souza MV; Boechat N; Krettli AU Antimicrob Agents Chemother; 2008 Nov; 52(11):3868-74. PubMed ID: 18710907 [TBL] [Abstract][Full Text] [Related]
24. Chloroquine resistance-conferring mutations in pfcrt give rise to a chloroquine-associated H+ leak from the malaria parasite's digestive vacuole. Lehane AM; Kirk K Antimicrob Agents Chemother; 2008 Dec; 52(12):4374-80. PubMed ID: 18852275 [TBL] [Abstract][Full Text] [Related]
25. Efflux of a range of antimalarial drugs and 'chloroquine resistance reversers' from the digestive vacuole in malaria parasites with mutant PfCRT. Lehane AM; Kirk K Mol Microbiol; 2010 Aug; 77(4):1039-51. PubMed ID: 20598081 [TBL] [Abstract][Full Text] [Related]
26. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation. Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ mBio; 2020 Jan; 11(1):. PubMed ID: 31992618 [TBL] [Abstract][Full Text] [Related]
27. Antimalarial properties and molecular docking analysis of compounds from Dioscorea bulbifera L. as new antimalarial agent candidates. Chaniad P; Mungthin M; Payaka A; Viriyavejakul P; Punsawad C BMC Complement Med Ther; 2021 May; 21(1):144. PubMed ID: 34006257 [TBL] [Abstract][Full Text] [Related]
28. High-Content Phenotypic Screen of a Focused TCAMS Drug Library Identifies Novel Disruptors of the Malaria Parasite Calcium Dynamics. Chia W; Gomez-Lorenzo MG; Castellote I; Tong JX; Chandramohanadas R; Thu Chu TT; Shen W; Go ML; de Cozar C; Crespo B; Almela MJ; Neria-Serrano F; Franco V; Gamo FJ; Tan KSW ACS Chem Biol; 2021 Nov; 16(11):2348-2372. PubMed ID: 34609851 [TBL] [Abstract][Full Text] [Related]
29. Loss of pH control in Plasmodium falciparum parasites subjected to oxidative stress. van Schalkwyk DA; Saliba KJ; Biagini GA; Bray PG; Kirk K PLoS One; 2013; 8(3):e58933. PubMed ID: 23536836 [TBL] [Abstract][Full Text] [Related]
30. Methods Used to Investigate the Edgar RCS; Counihan NA; McGowan S; de Koning-Ward TF Front Cell Infect Microbiol; 2021; 11():829823. PubMed ID: 35096663 [No Abstract] [Full Text] [Related]
31. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Moura PA; Dame JB; Fidock DA Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273 [TBL] [Abstract][Full Text] [Related]
32. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development. Deniskin R; Frame IJ; Sosa Y; Akabas MH Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473 [TBL] [Abstract][Full Text] [Related]
33. Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites. Kashyap A; Kaur R; Baldi A; Jain UK; Chandra R; Madan J Int J Biol Macromol; 2018 Jul; 114():161-168. PubMed ID: 29572147 [TBL] [Abstract][Full Text] [Related]
34. [In vitro susceptibility of P. falciparum isolates from Abidjan (Côte d'Ivoire) to quinine, artesunate and chloroquine]. Touré AO; Koné LP; Jambou R; Konan TD; Demba S; Beugre GE; Koné M Sante; 2008; 18(1):43-7. PubMed ID: 18684691 [TBL] [Abstract][Full Text] [Related]
35. Drug-induced permeabilization of parasite's digestive vacuole is a key trigger of programmed cell death in Plasmodium falciparum. Ch'ng JH; Liew K; Goh AS; Sidhartha E; Tan KS Cell Death Dis; 2011 Oct; 2(10):e216. PubMed ID: 21993392 [TBL] [Abstract][Full Text] [Related]
36. A Variant PfCRT Isoform Can Contribute to Dhingra SK; Redhi D; Combrinck JM; Yeo T; Okombo J; Henrich PP; Cowell AN; Gupta P; Stegman ML; Hoke JM; Cooper RA; Winzeler E; Mok S; Egan TJ; Fidock DA mBio; 2017 May; 8(3):. PubMed ID: 28487425 [TBL] [Abstract][Full Text] [Related]
37. Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies. de Souza GE; Bueno RV; de Souza JO; Zanini CL; Cruz FC; Oliva G; Guido RVC; Aguiar ACC Malar J; 2019 Dec; 18(1):447. PubMed ID: 31888654 [TBL] [Abstract][Full Text] [Related]
38. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. Yayon A; Cabantchik ZI; Ginsburg H EMBO J; 1984 Nov; 3(11):2695-700. PubMed ID: 6391917 [TBL] [Abstract][Full Text] [Related]
39. Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia. Chaorattanakawee S; Tyner SD; Lon C; Yingyuen K; Ruttvisutinunt W; Sundrakes S; Sai-gnam P; Johnson JD; Walsh DS; Saunders DL; Lanteri CA Malar J; 2013 Jul; 12():239. PubMed ID: 23849006 [TBL] [Abstract][Full Text] [Related]
40. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses. Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]